Instem said this week, than an undisclosed healthcare company has licensed its Centrus software suite and SRS platform to support ongoing drug research and development efforts.
The Centrus suite provides users with a single, secure environment to access, harmonize, and use early drug development information from a variety of sources, including data acquisition systems, warehouses, as well as partner and contract research applications. The suite includes Centrus submit, which lets users convert data into the Standard for Exchange of Non-Clinical Data, or SEND, format — a standard developed by the Clinical Data Interchange Standards Consortium for non-clinical data collected from animal toxicology studies.
Instem said its new customer has also licensed SRS, its genomic data integration platform, to help researchers access, integrate, and query SEND data being created from their own preclinical data collection system as well as SEND data received from their external study partners.
The financial details of the agreement are not being disclosed.